Italia markets close in 5 hours 21 minutes

Zealand Pharma A/S (0NZU.IL)

IOB - IOB Prezzo differito. Valuta in DKK.
Aggiungi a portafoglio
136,30-3,45 (-2,47%)
Al 10:38AM GMT. Mercato aperto.

Zealand Pharma A/S

Sydmarken 11
SOeborg
Copenhagen 2860
Denmark
45 88 77 36 00
https://www.zealandpharma.com

Settore/iHealthcare
SettoreBiotechnology
Impiegati a tempo pieno346

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Emmanuel Dulac Pharm.D., PharmD, Ph.D., MBACEO & Pres12,44MN/D1969
Mr. Matthew Donald DallasSr. VP & CFO5,67MN/D1975
Ms. Hanne Heidenheim BakSr. Project Director, R&D Operations Mang. and Employee Representative Director133kN/D1953
Mr. Adam Sinding Steensberg M.D.Exec. VP of R&D and Chief Medical Officer7,39MN/D1974
Mr. Ivan Mourits MøllerSr. VP of Technical Devel. & OperationsN/DN/D1972
Ms. Rie Schultz HansenVP of Discovery & InnovationN/DN/DN/D
Lani Pollworth MorvanInvestor Relations & Communications OfficerN/DN/DN/D
Mr. Mads KronborgHead of Investor Relations & CommunicationN/DN/DN/D
Søren Vitfell KellerHead of Legal AffairsN/DN/DN/D
Ms. Christina Sonnenborg BredalVP and Head of People & OrganizationN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2020 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in DKK.

Descrizione

Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin, Lyxumia, Soliqua 100/33, and Suliqua. Its product pipeline includes Dasiglucagon single use syringe or autoinjector that has completed Phase III clinical trials for the treatment of severe hypoglycemia; Dasiglucagon dual-hormone artificial pancreas has completed Phase II clinical trials for automated diabetes management; Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism and in Phase II clinical trials for post bariatric surgery hypoglycemia. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion; and Beta Bionics, Inc. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.

Governance aziendale

L'ISS Governance QualityScore di Zealand Pharma A/S al 26 settembre 2021 è 1. I criteri di valutazione fondamentali sono revisione: 3; Consiglio di Amministrazione: 2; diritti degli azionisti: 1; retribuzione: 1.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.